Abstract
The discovery of drugs for Alzheimer’s disease (AD) therapy that can also permeate the blood brain barrier (BBB) is very difficult owing to its specificity and restrictive nature. The BBB disruption or the administration of the drug directly into the brain is not an option due to toxic effects and low diffusion of the therapeutic molecule in the brain parenchyma. A promising approach for drug systemic delivery to the central nervous system is the use of nanosized carriers. The therapeutic potential of certain nanopharmaceuticals for AD has already been demonstrated in vivo after systemic delivery. They are based on i) conjugates of drug and monoclonal antibodies against BBB endogenous receptors; ii) cationized or end terminal protected proteins/peptides; iii) liposomes and polymeric nanoparticles coated with polysorbate 80, cationic macromolecules or antibodies against BBB receptors/amyloid beta-peptides. Optimization and further validation of these systems are needed.
Keywords: Alzheimer’s disease, Brain drug-targeting, blood brain barrier, parenteral route administration, monoclonal antibodies, liposomes, polymeric nanoparticles, therapeutic peptides.
Current Pharmaceutical Design
Title:Targeted Drug Delivery Across the Blood Brain Barrier in Alzheimer’s Disease
Volume: 19 Issue: 37
Author(s): Sandra Rocha
Affiliation:
Keywords: Alzheimer’s disease, Brain drug-targeting, blood brain barrier, parenteral route administration, monoclonal antibodies, liposomes, polymeric nanoparticles, therapeutic peptides.
Abstract: The discovery of drugs for Alzheimer’s disease (AD) therapy that can also permeate the blood brain barrier (BBB) is very difficult owing to its specificity and restrictive nature. The BBB disruption or the administration of the drug directly into the brain is not an option due to toxic effects and low diffusion of the therapeutic molecule in the brain parenchyma. A promising approach for drug systemic delivery to the central nervous system is the use of nanosized carriers. The therapeutic potential of certain nanopharmaceuticals for AD has already been demonstrated in vivo after systemic delivery. They are based on i) conjugates of drug and monoclonal antibodies against BBB endogenous receptors; ii) cationized or end terminal protected proteins/peptides; iii) liposomes and polymeric nanoparticles coated with polysorbate 80, cationic macromolecules or antibodies against BBB receptors/amyloid beta-peptides. Optimization and further validation of these systems are needed.
Export Options
About this article
Cite this article as:
Rocha Sandra, Targeted Drug Delivery Across the Blood Brain Barrier in Alzheimer’s Disease, Current Pharmaceutical Design 2013; 19 (37) . https://dx.doi.org/10.2174/13816128113199990613
DOI https://dx.doi.org/10.2174/13816128113199990613 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Plombage: A Forgotten Surgical Treatment for Pulmonary Tuberculosis
Current Respiratory Medicine Reviews Pilot Randomized Controlled Study of a Histamine Receptor Inverse Agonist in the Symptomatic Treatment of AD
Current Alzheimer Research Drug Delivery Systems for Brain Tumor Therapy
Current Pharmaceutical Design The Expanding Universe of Neurotrophic Factors: Therapeutic Potential in Aging and Age-Associated Disorders
Current Pharmaceutical Design Disrupted White Matter Networks from Subjective Memory Impairment to Amnestic Mild Cognitive Impairment
Current Alzheimer Research Mineralocorticoid Receptor Blockade in the Protection of Target Organ Damage
Cardiovascular & Hematological Agents in Medicinal Chemistry Reversal of Calcium Dysregulation as Potential Approach for Treating Alzheimer's Disease
Current Alzheimer Research Mitochondrial Disturbances, Tryptophan Metabolites and Neurodegeneration: Medicinal Chemistry Aspects
Current Medicinal Chemistry A Review of Wavelet Denoising in MRI and Ultrasound Brain Imaging
Current Medical Imaging Roles of IL-6-gp130 Signaling in Vascular Inflammation
Current Cardiology Reviews Progression of Mild Cognitive Impairment to Alzheimers or Vascular Dementia Versus Normative Aging Among Elderly Chinese
Current Alzheimer Research Molecular Basis of Inflammation and Insulin Resistance in Obesity
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Transforming Growth Factor-β Signaling in Motor Neuron Diseases
Current Molecular Medicine Humans Entrain to Sunlight - Impact of Social Jet Lag on Disease and Implications for Critical Illness
Current Pharmaceutical Design Detecting Non-cognitive Features of Prodromal Neurodegenerative Diseases
Current Aging Science C-1073 (Mifepristone) in the Adjunctive Treatment of Alzheimers Disease
Current Alzheimer Research Quantitative μPET Imaging of Cerebral Glucose Metabolism and Amyloidosis in the TASTPM Double Transgenic Mouse Model of Alzheimer’s Disease
Current Alzheimer Research Alzheimers Disease (AD) and Mild Cognitive Impairment (MCI) Patients are Characterized by Increased BDNF Serum Levels
Current Alzheimer Research Changes in the Expression of the Alzheimers Disease-Associated Presenilin Gene in Drosophila Heart Leads to Cardiac Dysfunction
Current Alzheimer Research Inflammation, Endothelial Dysfunction and Arterial Stiffness as Therapeutic Targets in Cardiovascular Medicine
Current Pharmaceutical Design